Thank you, Chair.
I'd like to direct my first questions to Dr. Joel Lexchin with a brief introductory comment. We heard about 140 peer-reviewed papers that you authored or co-authored, and that you've been working on this issue for 30 years. I know that a significant part of your career has been against the current, especially in the early years when you were like a voice in the wilderness on drug safety. I wanted to thank you and congratulate you, on the record, for your work in leading this for so many years.
Could you please comment, Dr. Lexchin, on why transparency in clinical trials is important for patients? In other words, how will it net benefit patients and improve their health, and reduce adverse drug reactions?